TP53 and B-cell chronic lymphocytic leukemia: The treatment landscape of CLL has changed considerably in the last decades with the introduction of new targeted agents leading to improved outcome for patients with CLL compared to standard chemo-immunotherapy, especially for those with high-risk features, as del17p13, TP53 mutations and unmutated immunoglobulin heavy chain (IGHV) genes.